Compare Organon & Co. Common Stock (OGN) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Twilio Inc — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Twilio Inc trades at $268.1 (market cap $43.25B). The key difference: Twilio Inc is far larger — about 11.9× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Twilio Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Twilio Inc for 56 Days on average.
| OGN | TWLO | |
|---|---|---|
Market Cap | $3.62B | $43.25B |
Volume | 2,892,999 | 1,616,308 |
Sector | Health | Technology |
52-Week High | $13.81 | $301.27 |
52-Week Low | $5.70 | $106.23 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $11.04B | $41.65B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Twilio stock trades at $271.12, down 4.08% today, amid mixed signals. The technical outlook is bullish based on moving averages, with key support at $268. Fundamentally, revenue grew to $5.07B in 2025, with net income turning positive at $33.83M after years of losses. Recent news highlights its upcoming addition to the S&P 500 index effective October 6, 2026, a positive catalyst for institutional interest.
The outlook is cautiously optimistic given strong analyst support (76.9% buy ratings) and a consensus price target of $257.59, though the stock trades above this level. Risks include high valuation multiples (P/E 38.89) and competitive pressures in customer engagement software. Earnings beats in recent quarters support growth momentum, but investors should weigh rich valuations against execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
